Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareJUNEL FE 1 20 vs 1 5 30
Comparative Pharmacology

JUNEL FE 1 20 vs 1 5 30 Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

JUNEL FE 1/20 vs 1 5 30

Head-to-head clinical comparison of therapeutic indices and safety profiles.

View JUNEL FE 1/20 Monograph
JUNEL FE 1/20
Oral Contraceptive
Category C
1 5 30
Pharmacology
Pending

Clinical Essentials

JUNEL FE 1/20
1 5 30
Mechanism of Action
JUNEL FE 1/20

Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.

1 5 30
Data Pending
Indications
JUNEL FE 1/20

Prevention of pregnancy,Treatment of moderate acne vulgaris (in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche),Management of menstrual disorders (off-label)

1 5 30
Data Pending
Standard Dosing
JUNEL FE 1/20

One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.

1 5 30
Data Pending
Direct Interaction
JUNEL FE 1/20
No Direct Interaction
1 5 30
No Direct Interaction

Pharmacokinetics

JUNEL FE 1/20
1 5 30
Half-Life
JUNEL FE 1/20

Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.

1 5 30
Data Pending
Metabolism
JUNEL FE 1/20

Special Populations

JUNEL FE 1/20
1 5 30
Renal Adjustments
JUNEL FE 1/20

No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia.

1 5 30
Data Pending
Hepatic Adjustments

Safety & Monitoring

JUNEL FE 1/20
1 5 30
Black Box Warnings
JUNEL FE 1/20
FDA Black Box Warning

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.

Pregnancy & Lactation

JUNEL FE 1/20
1 5 30
Teratogenic Risk
JUNEL FE 1/20

Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses).

1 5 30
Data Pending

Clinical Insights

JUNEL FE 1/20
1 5 30
Clinical Pearls
JUNEL FE 1/20

Junel Fe 1/20 is a combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone 1 mg. It is a low-dose pill; efficacy may be slightly lower than higher-dose pills. The iron supplement (ferrous fumarate) in the placebo pills is not intended for contraception; patients should not skip active pills. Missed pills increase risk of ovulation; if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception for 7 days. Counsel on signs of venous thromboembolism (VTE): sudden leg pain, chest pain, shortness of breath. Consider alternatives in migraine with aura, uncontrolled hypertension, or smokers over 35. Drug interactions include rifampin, certain anticonvulsants (phenytoin, carbamazepine), and St. John's Wort which may reduce efficacy.

1 5 30
Data Pending
Safety Verification

Known Interactions

JUNEL FE 1/20 Risks

No interactions on record

1 5 30 Risks

No interactions on record

Clinical Q&A

Frequently Asked Questions

1. What is the primary difference between JUNEL FE 1/20 and 1 5 30?

JUNEL FE 1/20 and 1 5 30 are distinct pharmacological agents. JUNEL FE 1/20 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyTreatment of moderate acne vulgaris (in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche)Management of menstrual disorders (off-label). 1 5 30 belongs to the indicated class and is primarily used for specified clinical guidelines. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.

2. Are JUNEL FE 1/20 and 1 5 30 safe during pregnancy?

The maternal-fetal safety profiles of these drugs differ. JUNEL FE 1/20 carries a safety status of Category C, whereas 1 5 30 safety is classified as Pending. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.

Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation).

1 5 30
Data Pending
Excretion
JUNEL FE 1/20

Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.

1 5 30
Data Pending
Protein Binding
JUNEL FE 1/20

Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG).

1 5 30
Data Pending
VD (L/kg)
JUNEL FE 1/20

Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution.

1 5 30
Data Pending
Bioavailability
JUNEL FE 1/20

Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%.

1 5 30
Data Pending
JUNEL FE 1/20

Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable.

1 5 30
Data Pending
Pediatric Dosing
JUNEL FE 1/20

Safety and efficacy not established in pediatric patients. Not indicated for use before menarche.

1 5 30
Data Pending
Geriatric Dosing
JUNEL FE 1/20

Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors.

1 5 30
Data Pending
1 5 30
No Black Box Warning
Warnings/Precautions
JUNEL FE 1/20
  • Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)
  • Hepatic neoplasia (benign and malignant)
  • Gallbladder disease
  • Hypertension
  • Carbohydrate and lipid metabolic effects
  • Headache
  • Bleeding irregularities
  • Depression
  • Ocular lesions (e.g., retinal thrombosis)
  • Carcinoma of the breast and reproductive organs
  • Use in pregnancy (discontinue if pregnancy occurs)
1 5 30
Data Pending
Contraindications
JUNEL FE 1/20
  • Thrombophlebitis, thromboembolic disorders, or history of these conditions
  • Cerebrovascular or coronary artery disease
  • Known or suspected breast cancer
  • Carcinoma of the endometrium or other estrogen-dependent neoplasia
  • Undiagnosed abnormal genital bleeding
  • Cholestatic jaundice of pregnancy or jaundice with prior pill use
  • Hepatic adenoma or carcinoma
  • Known or suspected pregnancy
  • Hypersensitivity to any component
  • Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations
1 5 30
Data Pending
Adverse Reactions
JUNEL FE 1/20
Data Pending
1 5 30
Data Pending
Food Interactions
JUNEL FE 1/20

No specific food restrictions. Grapefruit juice may theoretically increase estrogen levels but clinical significance is minimal; routine avoidance not required. Iron tablets (ferrous fumarate) may cause gastrointestinal upset; taking with food may reduce nausea. Avoid high-dose vitamin C supplements as they may increase estrogen absorption, but normal dietary intake is safe.

1 5 30
Data Pending
Lactation Summary
JUNEL FE 1/20

Small amounts of ethinyl estradiol and norethindrone (the active components) are excreted into breast milk. The M/P ratio is approximately 0.1-0.3 for ethinyl estradiol and 0.5-1.0 for norethindrone. Use is generally not recommended during breastfeeding as it may reduce milk production and quality. If used, monitor infant for jaundice and growth.

1 5 30
Data Pending
Pregnancy Dosing
JUNEL FE 1/20

Contraindicated; no dose adjustment is indicated as the drug should be discontinued immediately upon pregnancy detection.

1 5 30
Data Pending
Maternal Safety Status
JUNEL FE 1/20
Category C
1 5 30
Pending
Patient Counseling
JUNEL FE 1/20

Take one pill daily at the same time; the last 7 pills in each pack are iron tablets and do not provide contraception.,If you miss an active pill, take it as soon as you remember. If you miss two or more active pills, use a backup contraceptive method (e.g., condoms) for the next 7 days.,Vomiting or severe diarrhea within 4 hours of taking an active pill may reduce effectiveness; treat as a missed pill and consult your clinician.,Notify your clinician if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,Avoid smoking while on this medication, especially if over 35 years old, as it increases the risk of serious cardiovascular events.,Inform your clinician of all medications you take, including over-the-counter products and herbal supplements.

1 5 30
Data Pending